ARGINASE INHIBITORS AND METHODS OF USE

ChangeBridge: EPO Bulletin - Therapeutics (A61P)

Published March 25th, 2026

Detected April 1st, 2026

Summary

The European Patent Office published Merck Sharp & Dohme LLC's patent application EP3765006A1 for arginase inhibitor compounds and methods of use for treating cancer. The application lists 19 inventors and covers pharmaceutical compositions (A61K 31/195, A61K 31/69), chemical compounds (C07F 5/02), and therapeutic methods (A61P 35/00).

View original document View source feed page

What changed

The EPO published Merck Sharp & Dohme LLC's patent application EP3765006A1 for arginase inhibitors—compounds that target cancer metabolism. The application covers specific chemical compounds (A61K 31/195, A61K 31/69, C07F 5/02) and their use in treating proliferative diseases, particularly cancers (A61P 35/00). The patent designates all EPO member states.

Pharmaceutical companies and biotechnology firms developing cancer therapeutics should review this patent publication to assess potential freedom-to-operate implications. Competitors in the arginase inhibitor space should evaluate whether their compounds or methods fall within the scope of the pending claims.

Source document (simplified)

← EPO Patent Bulletin

ARGINASE INHIBITORS AND METHODS OF USE

Publication EP3765006A1 Kind: A1 Mar 25, 2026

Applicants

Merck Sharp & Dohme LLC

Inventors

ACHAB, Abdelghani Abe, CHILDERS, Matthew L., CUMMING, Jared N., FISCHER, Christian, GATHIAKA, Symon, GUNAYDIN, Hakan, LESBURG, Charles A., LI, Derun, LU, Min, PALANI, Anandan, PALTE, Rachel L., PU, Qinglin, SLOMAN, David L., SO, Sung-Sau, SUN, Chunrui, ZHANG, Hongjun

IPC Classifications

A61K 31/195 20060101AFI20220120BHEP A61K 31/69 20060101ALI20220120BHEP C07F 5/02 20060101ALI20220120BHEP A61P 35/00 20060101ALI20220120BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →